A Comprehensive Benchmark of Transcriptomic Biomarkers for Immune Checkpoint Blockades

SIMPLE SUMMARY: Immune checkpoint blockades (ICBs) therapy has produced durable clinical responses in many cancer types, but only a fraction of patients can benefit from ICB treatment. Previous studies have reported multiple transcriptomic biomarkers to predict ICB responses and improve treatment pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Hongen, Zhu, Xiuli, Cui, Ying, Xiong, Zhuang, Zong, Wenting, Bao, Yiming, Jia, Peilin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452274/
https://www.ncbi.nlm.nih.gov/pubmed/37627121
http://dx.doi.org/10.3390/cancers15164094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452274/
https://www.ncbi.nlm.nih.gov/pubmed/37627121
http://dx.doi.org/10.3390/cancers15164094

Ejemplares similares